Tolvaptan, sold under the brand name Samsca among others, is an aquaretic drug that functions as a selective, competitive vasopressin receptor 2 (V2) antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan was approved by the U.S. Food and Drug Administration (FDA) on May 19, 2009, and is sold by Otsuka Pharmaceutical Co. under the trade name Samsca. Tolvaptan, as Jynarque, was granted approval for medical use in the United States in April 2018.
via Wikipedia infobox
via PubMed
{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 470611744 | IUPAC_name = N-(4-{[(5R)-7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl}-3-methylphenyl)-2-methylbenzamide | image = (RS)-Tolvaptan Structural Formula V1.svg | image_class = skin-invert-image | image2 = Tolvaptan ball-and-stick model.png | image_class2 = bg-transparent
| tradename = Samsca, Jinarc, Jynarque, others | Drugs.com = | MedlinePlus = a609033 | DailyMedID = Tolvaptan | pregnancy_AU = | pregnancy_category = UK: Contraindicated | routes_of_administration = By mouth | ATC_prefix = C03 | ATC_suffix = XA01 | ATC_supplemental = | legal_AU = S4 | legal_AU_comment = | legal_CA = | legal_UK = POM | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_EU = Rx-only | legal_EU_comment = | legal_status = | protein_bound = 99% | metabolism = Liver (CYP3A4-mediated) | elimination_half-life = 12 hours (terminal) | excretion = | CAS_number_Ref = | CAS_number = 150683-30-0 | PubChem = 216237 | IUPHAR_ligand = 2226 | DrugBank_Ref = | DrugBank = DB06212 | ChemSpiderID_Ref = | ChemSpiderID = 187438 | UNII_Ref = | UNII = 21G72T1950 | ChEMBL_Ref = | ChEMBL = 344159 | ChEBI = 32246 | KEGG = D01213
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).